Society For Vascular Medicine Research Articles

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

29th Annual Meeting of the German Society for Angiology and the Society for Vascular Medicine. Frankfurt am Main 10.–13. September 2000

29th Annual Meeting of the German Society for Angiology and the Society for Vascular Medicine. Frankfurt am Main 10.–13. September 2000

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

News from the Society for Vascular Medicine and Biology

The Society’s journal, Vascular Medicine, has achieved citation status in Index Medicus. This is a significant achievement and the SVMB is extremely grateful to Mark Creager, Editor, for his outstanding leadership. Vascular Medicine provides a critical resource for the long-term development of this specialty and despite the proliferation of biomedical journals, Vascular Medicine is the only English language, professional journal, devoted solely to the field of vascular medicine. The mission of the SVMB is amplified by each new bridge created between vascular biology and the clinical needs of our patients. In this regard, the SVMB has a particular interest in the recent FDA approval of cilostazol, the first new claudication medication to enter American pharmacopoeia in nearly 20 years. Cilostazol will improve the ability of internists to ameliorate claudication symptoms in patients with PAD. Cilostazol (Pletal) has been shown to improve peak walking distance (the ambulatory claudication distance) in eight randomized clinical trials performed in the USA and the UK. It is expected that this

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

Society for Vascular Medicine and Biology abstracts

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology.

News from the Society for Vascular Medicine and Biology.

News from the Society for Vascular Medicine and Biology

News from the Society for Vascular Medicine and Biology